A near infrared fluorescent probe for hypoxia based on dicyanoisophorone and its application in Hela cells imaging
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.A new near-infrared fluorescent probe, DCI-Azo, effectively detects tumor hypoxia by sensing azo-reductase. This tool offers high sensitivity and selectivity for improved cancer diagnosis and therapy monitoring.
Area Of Science
- Biomedical Engineering
- Chemical Biology
- Medical Imaging
Background
- Tumor hypoxia accelerates metastasis and limits cancer treatment efficacy.
- Sensitive detection of hypoxia is crucial for effective cancer diagnosis and therapy.
Purpose Of The Study
- To develop a novel near-infrared (NIR) fluorescent probe, DCI-Azo, for specific and sensitive detection of tumor hypoxia.
- To evaluate the probe's performance in vitro and in vivo for potential applications in cancer imaging.
Main Methods
- A one-pot synthesis method was used to create the NIR fluorophore DCI-Am (97% yield).
- DCI-Azo was designed and synthesized based on DCI-Am.
- In vitro hypoxia detection was assessed using sodium dithionite and rat liver microsomes.
- In vivo imaging was performed in Hela cells and a mouse tumor model.
Main Results
- DCI-Azo exhibits NIR emission (650 nm), large Stokes shift (>160 nm), high sensitivity (LOD 0.53 μg/mL), selectivity, and low cytotoxicity (>80% cell viability).
- A ~26-fold increase in fluorescence was observed in Hela cells under hypoxic conditions (1% O2).
- Tumor tissues showed a ~5-fold fluorescence enhancement compared to normal tissues in vivo.
Conclusions
- DCI-Azo is a sensitive, selective, and low-cytotoxicity probe for hypoxia detection.
- The probe demonstrates significant potential as a versatile tool for in vivo imaging and cancer diagnosis.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.